Table 2 Association of TRIM5 rs3824949 and TRIM22 rs1063303, rs7113258 polymorphism with significant fibrosis (F ≥ 2) at baseline and sustained virological response (SVR) in HIV/HCV coinfected patients on HCV therapy

TRIM5  rs3824949 (Recessive)

 F ≥ 2 (n = 287)

31.6 % (142/225)

48.7 % (39/62)

0.976

0.84 (0.46–1.55)

0.589

 SVR (n = 318)

50.8 % (127/250)

67.6 % (46/68)

0.013

2.58 (1.23–5.39)

0.012

TRIM22  rs1063303 (Recessive)

 F ≥ 2 (n = 286)

59.8 %(140/234)

76.9 % (40/52)

0.021

2.19 (1.06–4.53)

0.034

 SVR (n = 317)

55.6 % (145/261)

48.2 % (27/56)

0.317

0.89 (0.41–1.91)

0.760

F ≥ 2 (n = 287)

63.3 % (124/196)

63.7 % (58/91)

0.939

1.06 (0.62; 1.82)

0.829

SVR (n = 317)

49.8 % (107/215)

64.7 % (66/102)

0.013

1.88 (1.03–3.38)

0.041